2m 2m 2m 2m 2m 2m 2m
TREVI THERAPEUTI (TRVI)
NASDAQ
$17.36-$0.36 (-2.00%)
Price as of Jun 23, 2026 7:16 PM EDT- $2.5BMarket Cap
- 208.00%1-Year Change
- BiotechnologyIndustry
TREVI THERAPEUTI (TRVI)
$17.36-$0.36 (-2.00%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -33.5M -14.98% | -39.4M +66.27% | -23.7M +19.41% | -19.8M -13.71% | |
Depreciation and Amortization Expense | 144,000 -2.04% | 147,000 +19.51% | 123,000 +186.05% | 43,000 -14.00% | |
Total Operating Expenses | 49.3M -4.26% | 51.5M +51.89% | 33.9M +13.43% | 29.9M -7.91% | |
Operating Profit | -49.3M -4.26% | -51.5M +51.89% | -33.9M +13.43% | -29.9M -7.91% | |
Interest Income | 6.5M +81.45% | 3.6M N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | -382,000 -2.30% | -391,000 -66.38% | -1.2M -3.24% | |
Interest Income and Expense and Net | 6.5M +102.98% | 3.2M +923.53% | -391,000 -66.38% | -1.2M -3.24% | |
Total Nonoperating Income and Expense | 6.5M +81.55% | 3.6M -25.76% | 4.8M +571.21% | 719,000 +148.42% | |
Income before Taxes | -42.8M -10.68% | -47.9M +64.76% | -29.1M -0.31% | -29.2M -14.05% | |
Income Taxes | -64,000 +113.33% | -30,000 -6.25% | -32,000 -11.11% | -36,000 +71.43% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -42.8M -10.75% | -47.9M +64.84% | -29.1M -0.30% | -29.2M -14.11% | |
Net Income from Continuing Operations Applicable to Common | -42.8M -10.68% | -47.9M +64.76% | -29.1M -0.31% | -29.2M -14.05% | |
Basic EPS and Net Income | -0.32 -31.91% | -0.47 +62.07% | -0.29 -35.56% | -0.45 -69.80% | |
Diluted EPS and Net Income | -0.32 -31.91% | -0.47 +62.07% | -0.29 -35.56% | -0.45 -69.80% | |
Basic Weighted Average Shares | 134.7M +32.14% | 102.0M +2.97% | 99.0M +53.44% | 64.5M +182.56% | |
Diluted Weighted Average Shares | 134.7M +32.14% | 102.0M +2.97% | 99.0M +53.44% | 64.5M +182.56% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 18.9M -44.53% | 34.1M +5.25% | 32.4M +157.34% | 12.6M -65.82% | |
Short-Term Investments | 169.3M +130.32% | 73.5M +45.38% | 50.6M -53.14% | 107.9M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 188.3M +74.93% | 107.6M +29.71% | 83.0M -31.15% | 120.5M +227.21% | |
Total Current Assets | 191.7M +75.14% | 109.4M +24.99% | 87.5M -28.60% | 122.6M +223.04% | |
Accumulated Depreciation | 359,000 +57.46% | 228,000 +70.15% | 134,000 -40.44% | 225,000 +23.63% | |
Property and Plant and Equipment and Net | 178,000 +13.38% | 157,000 -27.31% | 216,000 +27.06% | 170,000 +220.75% | |
Total Long-Term Assets | 928,000 +281.89% | 243,000 -18.18% | 297,000 +44.88% | 205,000 -38.62% | |
Total Assets | 193.4M +74.43% | 110.9M +24.05% | 89.4M -27.32% | 123.0M +219.73% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | 7.0M 0.00% | 7.0M +20.01% | |
Total Current Liabilities | 9.7M -7.23% | 10.5M +80.44% | 5.8M -56.54% | 13.4M +5.31% | |
Total Long-Term Debt | N/A N/A | 5.2M +141.75% | 2.2M 0.00% | 2.2M -75.14% | |
Total Long-Term Liabilities | 446,000 -40.29% | 747,000 +24,800.00% | 3,000 0.00% | 3,000 -87.50% | |
Total Liabilities | 10.2M -9.43% | 11.3M +64.18% | 6.9M -55.93% | 15.6M -27.31% | |
Retained Earnings | -329.8M +14.90% | -287.0M +20.04% | -239.1M +13.84% | -210.1M +16.11% | |
Total Stockholders Equity | 183.2M +83.90% | 99.6M +20.71% | 82.5M -23.18% | 107.5M +529.34% | |
Total Shares Outstanding | 128.3M +37.08% | 93.6M +37.08% | 68.3M +13.91% | 59.9M +110.29% | |
Cash Flow | |||||
Cash from Operating Activities | -42.1M +10.02% | -38.3M +20.64% | -31.7M +12.55% | -28.2M -2.66% | |
Capital Expenditures | 12,000 -65.71% | 35,000 -74.45% | 137,000 -13.84% | 159,000 +396.88% | |
Cash from Investing Activities | -94.1M +337.14% | -21.5M -136.23% | 59.4M +155.35% | -107.4M +335,440.63% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 121.0M +96.82% | 61.5M +877.29% | -7.9M -107.11% | 111.3M +435.77% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | -28.10% -41.26% | -47.84% +74.81% | -27.37% -24.20% | -36.10% -54.47% | |
Return on Equity | -30.23% -42.52% | -52.59% +71.91% | -30.59% -34.65% | -46.82% -69.41% | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 19.66 +88.80% | 10.41 -30.73% | 15.03 +64.28% | 9.15 +206.74% | |
Cash Ratio | 1.94 -40.21% | 3.24 -41.67% | 5.56 +492.09% | 0.94 -67.54% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | 0.11 +30.16% | 0.09 -89.96% | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | 0.10 +37.63% | 0.07 -80.24% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow